These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35330827)

  • 1. Specific
    Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
    Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dacomitinib exhibits promising activity against the rare
    Yang G; Liu R; Tang X
    Heliyon; 2024 May; 10(9):e30312. PubMed ID: 38707278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting
    Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
    Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib.
    Li BT; Lee A; O'Toole S; Cooper W; Yu B; Chaft JE; Arcila ME; Kris MG; Pavlakis N
    Lung Cancer; 2015 Dec; 90(3):617-9. PubMed ID: 26559459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
    Yang S; Wang Y; Zhao C; Li X; Liu Q; Mao S; Liu Y; Yu X; Wang W; Tian Q; Pan Y; Xiong A; Chen B; Gao G; Li W; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Transl Lung Cancer Res; 2021 Feb; 10(2):753-765. PubMed ID: 33718019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring
    He Y; Huang H; Xu M; Fu Z; Zhang X; Chen X; Guo W
    Transl Cancer Res; 2022 Jun; 11(6):1819-1823. PubMed ID: 35836522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
    Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
    Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.
    Gan J; Huang Y; Liao J; Pang L; Fang W
    Onco Targets Ther; 2021; 14():5297-5307. PubMed ID: 34824536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: a retrospective ATLAS cohort study.
    Yang G; Liu R; Li P; Yang Y; Wang Y; Mao H; Tang X
    Discov Oncol; 2024 Jul; 15(1):285. PubMed ID: 39012378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
    Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
    Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
    Zhao S; Fang W; Pan H; Yang Y; Liang Y; Yang L; Dong X; Zhan J; Wang K; Zhang L
    J Thorac Oncol; 2020 Jun; 15(6):962-972. PubMed ID: 32036069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of afatinib in patients with
    Zhou N; Zhao J; Huang X; Shen H; Li W; Xu Z; Xia Y
    Transl Cancer Res; 2020 May; 9(5):3634-3642. PubMed ID: 35117726
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Yang G; Yang Y; Hu J; Xu H; Zhang S; Wang Y
    Front Pharmacol; 2022; 13():984503. PubMed ID: 36425568
    [No Abstract]   [Full Text] [Related]  

  • 18. Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study.
    Yang Y; Yang G; Li W; Hao X; Zhang S; Ai X; Lei S; Xu H; Wang Y
    Thorac Cancer; 2023 Nov; 14(33):3275-3281. PubMed ID: 37740599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
    Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
    Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment.
    Xu M; Wang Y; Shao K; Hao Y; Song Z
    Clin Transl Oncol; 2024 May; ():. PubMed ID: 38795256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.